Amarin Corporation plc (NasdaqCM: AMRN)
Health Care · Biotechnology · IE
$12.03
-2.59% today · -34.0% 1Y
Amarin Corporation plc (NasdaqCM: AMRN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $254.11M and employs 80 people.
Over the last twelve months the share price has lost 34.0%, trading between 11.83 and 20.90.
Tweenvest scores Amarin Corporation plc across four factors: quality 64/100, value 57/100, growth 0/100. Its strongest factor is quality.
AMRN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $254.11M
- Revenue (TTM)
- $186.23M
- P/E
- —
- EPS
- -1.30
- Dividend yield
- —
- Beta (5Y)
- 0.77
- 52-week high
- $20.90
- 52-week low
- $11.83
- Avg volume (3M)
- —
- Shares outstanding
- 21.12M
- Employees
- 80
- Next earnings
- —
About Amarin Corporation plc
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
- ISIN
- US0231114044
- Founded
- 1989
- Listed since
- Apr 1, 1993
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Healios K.K.TSE: 4593 | $258.52M | ¥302.00 | +5.23% |
| Upstream Bio, Inc.NasdaqGS: UPB | $257.42M | $4.70 | -6.75% |
| PharmaEngine, Inc.TPEX: 4162 | $257.02M | NT$57.20 | +3.25% |
| Immuneering CorporationNasdaqGM: IMRX | $254.91M | $3.94 | -3.19% |
| Intelligene Inc.TPEX: 7832 | $253.95M | NT$14.00 | +2.56% |
| Vicore Pharma Holding AB (publ)OM: VICO | $253.39M | Skr9.00 | -3.43% |
| Adimmune CorporationTWSE: 4142 | $253.10M | NT$19.20 | +6.67% |
| Lineage Cell Therapeutics, Inc.NYSEAM: LCTX | $251.39M | $0.99 | +6.85% |
Figures last refreshed Oct 11, 2026.